Skip to main content

MoneyWorks4Me

Bajaj Healthcare informs about press release

19 Mar 2025 Evaluate
Bajaj Healthcare has informed that Bajaj Healthcare has received recommendation from Subject Expert Committee (SEC) (Neurology & Psychiatry) of Central Drugs Standard Control Organisation (CDSCO) to conduct Phase III clinical trials for Cenobamate Tablets 12.5mg, 25mg, 50mg, 100mg, 150mg & 200mg. The press release in this regard, being issued by the Company.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1762.95
Dr. Reddys Labs. 1338.50
Cipla 1357.00
Lupin 1998.00
Zydus Lifesciences 1186.00
View more..